ACOG Stock Summary and Trading Ideas (Alpha Cognition | NASDAQ:ACOG)

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Alpha Cognition trades on the NASDAQ stock market under the symbol ACOG.

As of December 12, 2025, ACOG stock price declined to $5.31 with 109,485 million shares trading.

ACOG has a beta of 1.53, meaning it tends to be more sensitive to market movements. ACOG has a correlation of 0.13 to the broad based SPY ETF.

ACOG has a market cap of $115.45 million. This is considered a Micro Cap stock.

Last quarter Alpha Cognition reported $3 million in Revenue and -$.30 earnings per share. This beat revenue expectation by $100,800 and exceeded earnings estimates by $.15.

ACOG has underperformed the market in the last year with a price return of -7.5% while the SPY ETF gained +14.0%. ACOG has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -45.8% and -11.8%, respectively, while the SPY returned +4.0% and -0.2%, respectively.

ACOG support price is $5.52 and resistance is $6.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACOG shares will trade within this expected range on the day.